# Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease

> **NCT00002145** · PHASE3 · COMPLETED · sponsor: **Astra USA** · enrollment: 145 (—)

## Conditions studied

- HIV Infections
- Gastrointestinal Diseases

## Interventions

- **DRUG:** Foscarnet sodium

## Key facts

- **NCT ID:** NCT00002145
- **Lead sponsor:** Astra USA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 145 (—)
- **Last updated:** 2005-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002145, "Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00002145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*